TGFB1 and osteogenesis imperfecta: Importantly, effects on bone resorption and bone mass were only observed following administration of losartan at concentrations shown to reduce TGFβ secretion (0.6 g/L) suggesting that reduced activity of TGF is critical for reduced bone resorption in this model of OI (Fig. 2).